Chinese Time Trade-Off Values for EQ-5D Health States
To generate a Chinese general population–based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method. The study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a...
Saved in:
Published in | Value in health Vol. 17; no. 5; pp. 597 - 604 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.07.2014
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 1098-3015 1524-4733 1524-4733 |
DOI | 10.1016/j.jval.2014.05.007 |
Cover
Loading…
Abstract | To generate a Chinese general population–based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method.
The study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a subset of 97 health states defined by the EQ-5D-3L descriptive system were directly elicited from the study sample using a modified Measurement and Valuation of Health protocol, with each respondent valuing 13 of the health states. The utility values for all 243 EQ-5D-3L health states were estimated on the basis of econometric models at both individual and aggregate levels. Various linear regression models using different model specifications were examined to determine the best model using predefined model selection criteria.
The N3 model based on ordinary least square regression at the aggregate level yielded the best model fit, with a mean absolute error of 0.020, 7 and 0 states for which prediction errors were greater than 0.05 and 0.10, respectively, in absolute magnitude. This model passed tests for model misspecification (F = 2.7; P = 0.0509, Ramsey Regression Equation Specification Error Test), heteroskedasticity (χ2 = 0.97; P = 0.3254, Breusch-Pagan/Cook-Weisberg test), and normality of the residuals (χ2 = 1.285; P = 0.5259, Jarque-Bera test). The range of the predicted values (−0.149 to 0.887) was similar to those estimated in other countries.
The study successfully developed Chinese utility values for EQ-5D-3L health states using the time trade-off method. It is the first attempt ever to develop a standardized instrument for quantifying quality-adjusted life-years in China. |
---|---|
AbstractList | AbstractObjectiveTo generate a Chinese general population–based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method. MethodsThe study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a subset of 97 health states defined by the EQ-5D-3L descriptive system were directly elicited from the study sample using a modified Measurement and Valuation of Health protocol, with each respondent valuing 13 of the health states. The utility values for all 243 EQ-5D-3L health states were estimated on the basis of econometric models at both individual and aggregate levels. Various linear regression models using different model specifications were examined to determine the best model using predefined model selection criteria. ResultsThe N3 model based on ordinary least square regression at the aggregate level yielded the best model fit, with a mean absolute error of 0.020, 7 and 0 states for which prediction errors were greater than 0.05 and 0.10, respectively, in absolute magnitude. This model passed tests for model misspecification (F = 2.7; P = 0.0509, Ramsey Regression Equation Specification Error Test), heteroskedasticity (χ 2 = 0.97; P = 0.3254, Breusch-Pagan/Cook-Weisberg test), and normality of the residuals (χ 2 = 1.285; P = 0.5259, Jarque-Bera test). The range of the predicted values (−0.149 to 0.887) was similar to those estimated in other countries. ConclusionsThe study successfully developed Chinese utility values for EQ-5D-3L health states using the time trade-off method. It is the first attempt ever to develop a standardized instrument for quantifying quality-adjusted life-years in China. To generate a Chinese general population–based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method. The study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a subset of 97 health states defined by the EQ-5D-3L descriptive system were directly elicited from the study sample using a modified Measurement and Valuation of Health protocol, with each respondent valuing 13 of the health states. The utility values for all 243 EQ-5D-3L health states were estimated on the basis of econometric models at both individual and aggregate levels. Various linear regression models using different model specifications were examined to determine the best model using predefined model selection criteria. The N3 model based on ordinary least square regression at the aggregate level yielded the best model fit, with a mean absolute error of 0.020, 7 and 0 states for which prediction errors were greater than 0.05 and 0.10, respectively, in absolute magnitude. This model passed tests for model misspecification (F = 2.7; P = 0.0509, Ramsey Regression Equation Specification Error Test), heteroskedasticity (χ2 = 0.97; P = 0.3254, Breusch-Pagan/Cook-Weisberg test), and normality of the residuals (χ2 = 1.285; P = 0.5259, Jarque-Bera test). The range of the predicted values (−0.149 to 0.887) was similar to those estimated in other countries. The study successfully developed Chinese utility values for EQ-5D-3L health states using the time trade-off method. It is the first attempt ever to develop a standardized instrument for quantifying quality-adjusted life-years in China. To generate a Chinese general population-based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method.OBJECTIVETo generate a Chinese general population-based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method.The study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a subset of 97 health states defined by the EQ-5D-3L descriptive system were directly elicited from the study sample using a modified Measurement and Valuation of Health protocol, with each respondent valuing 13 of the health states. The utility values for all 243 EQ-5D-3L health states were estimated on the basis of econometric models at both individual and aggregate levels. Various linear regression models using different model specifications were examined to determine the best model using predefined model selection criteria.METHODSThe study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a subset of 97 health states defined by the EQ-5D-3L descriptive system were directly elicited from the study sample using a modified Measurement and Valuation of Health protocol, with each respondent valuing 13 of the health states. The utility values for all 243 EQ-5D-3L health states were estimated on the basis of econometric models at both individual and aggregate levels. Various linear regression models using different model specifications were examined to determine the best model using predefined model selection criteria.The N3 model based on ordinary least square regression at the aggregate level yielded the best model fit, with a mean absolute error of 0.020, 7 and 0 states for which prediction errors were greater than 0.05 and 0.10, respectively, in absolute magnitude. This model passed tests for model misspecification (F = 2.7; P = 0.0509, Ramsey Regression Equation Specification Error Test), heteroskedasticity (χ(2) = 0.97; P = 0.3254, Breusch-Pagan/Cook-Weisberg test), and normality of the residuals (χ(2) = 1.285; P = 0.5259, Jarque-Bera test). The range of the predicted values (-0.149 to 0.887) was similar to those estimated in other countries.RESULTSThe N3 model based on ordinary least square regression at the aggregate level yielded the best model fit, with a mean absolute error of 0.020, 7 and 0 states for which prediction errors were greater than 0.05 and 0.10, respectively, in absolute magnitude. This model passed tests for model misspecification (F = 2.7; P = 0.0509, Ramsey Regression Equation Specification Error Test), heteroskedasticity (χ(2) = 0.97; P = 0.3254, Breusch-Pagan/Cook-Weisberg test), and normality of the residuals (χ(2) = 1.285; P = 0.5259, Jarque-Bera test). The range of the predicted values (-0.149 to 0.887) was similar to those estimated in other countries.The study successfully developed Chinese utility values for EQ-5D-3L health states using the time trade-off method. It is the first attempt ever to develop a standardized instrument for quantifying quality-adjusted life-years in China.CONCLUSIONSThe study successfully developed Chinese utility values for EQ-5D-3L health states using the time trade-off method. It is the first attempt ever to develop a standardized instrument for quantifying quality-adjusted life-years in China. To generate a Chinese general population-based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method. The study sample was drawn from five cities in China: Beijing, Guangzhou, Shenyang, Chengdu, and Nanjing, using a quota sampling method. Utility values for a subset of 97 health states defined by the EQ-5D-3L descriptive system were directly elicited from the study sample using a modified Measurement and Valuation of Health protocol, with each respondent valuing 13 of the health states. The utility values for all 243 EQ-5D-3L health states were estimated on the basis of econometric models at both individual and aggregate levels. Various linear regression models using different model specifications were examined to determine the best model using predefined model selection criteria. The N3 model based on ordinary least square regression at the aggregate level yielded the best model fit, with a mean absolute error of 0.020, 7 and 0 states for which prediction errors were greater than 0.05 and 0.10, respectively, in absolute magnitude. This model passed tests for model misspecification (F = 2.7; P = 0.0509, Ramsey Regression Equation Specification Error Test), heteroskedasticity (χ(2) = 0.97; P = 0.3254, Breusch-Pagan/Cook-Weisberg test), and normality of the residuals (χ(2) = 1.285; P = 0.5259, Jarque-Bera test). The range of the predicted values (-0.149 to 0.887) was similar to those estimated in other countries. The study successfully developed Chinese utility values for EQ-5D-3L health states using the time trade-off method. It is the first attempt ever to develop a standardized instrument for quantifying quality-adjusted life-years in China. |
Author | Luo, Nan Liu, Gordon G. Li, Minghui Wu, Hongyan Gao, Chen |
Author_xml | – sequence: 1 givenname: Gordon G. surname: Liu fullname: Liu, Gordon G. organization: National School of Development, Peking University, Beijing, China – sequence: 2 givenname: Hongyan surname: Wu fullname: Wu, Hongyan organization: School of Medicine and Health Management, Guiyang Medical University, Guiyang, China – sequence: 3 givenname: Minghui surname: Li fullname: Li, Minghui organization: South Carolina College of Pharmacy, University of South Carolina, Columbia, SC – sequence: 4 givenname: Chen surname: Gao fullname: Gao, Chen organization: Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China – sequence: 5 givenname: Nan surname: Luo fullname: Luo, Nan email: nan_luo@nuhs.edu.sg organization: Saw Swee Hock School of Public Health, National University of Singapore, Singapore |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28765635$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/25128053$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkl9rFTEQxYNU7B_9Aj7Ivgi-7DpJdrJZEUGu1QqFIq2-htzsLM26N9smewv99ma5twgF60uSh985M3Myx-wgTIEYe82h4sDV-6Ea7uxYCeB1BVgBNM_YEUdRl3Uj5UF-Q6tLCRwP2XFKAwAoKfAFOxTIhQaURwxX1z5QouLKb_IRbUflRd8Xv-y4pVT0UyxOf5T4pTgjO87XxeVsZ0ov2fPejole7e8T9vPr6dXqrDy_-PZ99fm8dChwLlG1QqDU3bq3iARcNK3uFDU1t6oBp4Tgqmtyg33b9Ly1om5pjaQ0pzW1IE_Yu53vTZxucz-z2fjkaBxtoGmbDEeUDV9qZPTNHt2uN9SZm-g3Nt6bh1Ez8HYP2OTs2EcbnE9_Od0oVBIzp3eci1NKkXrjfB7aT2GO1o-Gg1nSN4NZ0jdL-gbQ5PSzVDySPrg_Kfq4E1EO8s5TNMl5Co46H8nNppv80_JPj-Ru9MHnCX_TPaVh2saQv8hwk4QBc7nsxLISvAautdDZ4MO_Df5X_Q8wwcFj |
CitedBy_id | crossref_primary_10_1080_02713683_2024_2355659 crossref_primary_10_1007_s00520_023_08240_1 crossref_primary_10_1080_03007995_2023_2178081 crossref_primary_10_1186_s12955_022_02076_9 crossref_primary_10_1007_s12020_019_02129_y crossref_primary_10_1111_ecc_13283 crossref_primary_10_1111_os_12925 crossref_primary_10_1007_s11136_018_1928_y crossref_primary_10_1007_s11136_021_02786_5 crossref_primary_10_1038_s41598_023_33248_2 crossref_primary_10_1371_journal_pone_0263912 crossref_primary_10_1186_s12939_023_02057_4 crossref_primary_10_1038_srep37838 crossref_primary_10_1016_j_phymed_2022_154391 crossref_primary_10_2147_NDT_S230403 crossref_primary_10_1186_s12939_020_1148_2 crossref_primary_10_1111_ggi_13895 crossref_primary_10_1186_s12955_022_01988_w crossref_primary_10_1016_j_jval_2020_12_019 crossref_primary_10_1097_SLA_0000000000006149 crossref_primary_10_1371_journal_pone_0175847 crossref_primary_10_1186_s12889_020_10038_3 crossref_primary_10_2147_JMDH_S436486 crossref_primary_10_1056_NEJMoa2314741 crossref_primary_10_1038_s41598_022_13910_x crossref_primary_10_1186_s13013_016_0083_x crossref_primary_10_1371_journal_pone_0302592 crossref_primary_10_3389_fneur_2025_1551332 crossref_primary_10_3389_fpubh_2021_654822 crossref_primary_10_1186_s12955_019_1109_x crossref_primary_10_1186_s12955_022_01917_x crossref_primary_10_1080_14737167_2022_2091546 crossref_primary_10_1016_j_vhri_2017_03_006 crossref_primary_10_1007_s10198_020_01233_5 crossref_primary_10_1016_j_sleep_2022_12_001 crossref_primary_10_1007_s00586_017_5330_1 crossref_primary_10_1186_s12939_019_1099_7 crossref_primary_10_1177_00469580241264187 crossref_primary_10_1038_s41371_018_0092_8 crossref_primary_10_1016_j_breast_2018_03_004 crossref_primary_10_1097_MD_0000000000014719 crossref_primary_10_1007_s00520_020_05729_x crossref_primary_10_1186_s12957_022_02619_w crossref_primary_10_1007_s00592_020_01618_1 crossref_primary_10_1007_s40273_020_00997_1 crossref_primary_10_1007_s12072_021_10240_4 crossref_primary_10_1136_bmjopen_2023_079305 crossref_primary_10_1186_s12955_023_02180_4 crossref_primary_10_1016_j_bja_2023_06_029 crossref_primary_10_1111_inr_12333 crossref_primary_10_1186_s12955_024_02276_5 crossref_primary_10_1016_j_chest_2022_12_037 crossref_primary_10_1186_s12905_015_0190_5 crossref_primary_10_1186_s12955_020_01476_z crossref_primary_10_1007_s11096_019_00870_y crossref_primary_10_3389_fpubh_2022_961019 crossref_primary_10_1186_s12889_024_20999_4 crossref_primary_10_1186_s12916_022_02601_z crossref_primary_10_1080_13696998_2023_2207742 crossref_primary_10_2196_18333 crossref_primary_10_3389_fonc_2022_1016258 crossref_primary_10_7189_jogh_11_08001 crossref_primary_10_1007_s40273_022_01151_9 crossref_primary_10_1186_s12889_021_11414_3 crossref_primary_10_1007_s11136_021_02853_x crossref_primary_10_1111_iwj_13907 crossref_primary_10_2196_29906 crossref_primary_10_1097_BRS_0000000000002287 crossref_primary_10_1186_s12879_017_2801_2 crossref_primary_10_1007_s11136_020_02551_0 crossref_primary_10_3389_fpubh_2024_1334081 crossref_primary_10_1016_j_ijnurstu_2020_103703 crossref_primary_10_1007_s11136_023_03394_1 crossref_primary_10_1136_bmjopen_2017_015880 crossref_primary_10_1371_journal_pone_0184266 crossref_primary_10_1007_s11205_015_1221_1 crossref_primary_10_3389_fpubh_2020_507785 crossref_primary_10_1016_j_jval_2018_04_1370 crossref_primary_10_1136_bmjopen_2023_072854 crossref_primary_10_1213_ANE_0000000000005841 crossref_primary_10_1016_j_jval_2020_06_010 crossref_primary_10_1016_j_vhri_2021_04_007 crossref_primary_10_1186_s12889_022_13146_4 crossref_primary_10_1007_s11136_014_0902_6 crossref_primary_10_1007_s11136_020_02636_w crossref_primary_10_3233_JAD_240583 crossref_primary_10_1002_hpm_2851 crossref_primary_10_2147_JIR_S282249 crossref_primary_10_1111_1753_0407_13294 crossref_primary_10_1111_papr_12931 crossref_primary_10_1007_s00198_019_05173_6 crossref_primary_10_1016_j_jenvman_2023_117619 crossref_primary_10_1007_s12603_016_0784_0 crossref_primary_10_1016_j_archger_2018_01_008 crossref_primary_10_1007_s10198_014_0635_z crossref_primary_10_1007_s12603_019_1189_7 crossref_primary_10_1111_cns_12329 crossref_primary_10_1186_s12955_024_02315_1 crossref_primary_10_1371_journal_pone_0238980 crossref_primary_10_1007_s40258_022_00732_1 crossref_primary_10_1186_s12939_020_01348_4 crossref_primary_10_1186_s12889_019_7351_7 crossref_primary_10_1007_s12603_020_1327_2 crossref_primary_10_1080_13548506_2020_1856896 crossref_primary_10_1007_s10198_022_01465_7 crossref_primary_10_1177_0272989X18778295 crossref_primary_10_3390_ijerph20010475 crossref_primary_10_1186_s12889_023_15075_2 crossref_primary_10_62347_XKUJ3012 crossref_primary_10_1038_s41467_023_39483_5 crossref_primary_10_1097_BRS_0000000000003116 crossref_primary_10_3389_fpubh_2021_713480 crossref_primary_10_2340_jrm_v56_24102 crossref_primary_10_1007_s40520_023_02656_9 crossref_primary_10_1097_BRS_0000000000002939 crossref_primary_10_1371_journal_pone_0164334 crossref_primary_10_1001_jamanetworkopen_2023_55564 crossref_primary_10_1136_bmjopen_2018_024080 crossref_primary_10_1186_s40064_016_3613_3 crossref_primary_10_1177_2396987316683780 crossref_primary_10_2196_22288 crossref_primary_10_1016_j_gie_2021_08_008 crossref_primary_10_1016_j_jval_2016_11_016 crossref_primary_10_1016_S2468_1253_21_00313_7 crossref_primary_10_1111_os_13904 crossref_primary_10_1186_s12955_018_0905_z crossref_primary_10_1161_STROKEAHA_119_027639 crossref_primary_10_1186_s12955_018_0865_3 crossref_primary_10_1007_s40273_016_0404_1 crossref_primary_10_1007_s40273_022_01172_4 crossref_primary_10_1186_s12877_024_05093_z crossref_primary_10_1007_s11136_017_1614_5 crossref_primary_10_1097_MD_0000000000034718 crossref_primary_10_1186_s12955_018_1036_2 crossref_primary_10_1007_s44197_021_00028_y crossref_primary_10_1016_j_jval_2015_10_010 crossref_primary_10_1111_sms_14771 crossref_primary_10_1177_0194599818800477 crossref_primary_10_1007_s11136_020_02749_2 crossref_primary_10_1007_s40273_018_0623_8 crossref_primary_10_2147_JPR_S289018 crossref_primary_10_1016_j_vhri_2023_07_004 crossref_primary_10_1186_s12889_024_20575_w crossref_primary_10_1007_s11136_024_03776_z crossref_primary_10_1007_s11136_020_02436_2 crossref_primary_10_1016_j_jdin_2020_03_003 crossref_primary_10_2217_cer_2016_0086 crossref_primary_10_1002_dmrr_3053 crossref_primary_10_1186_s12955_023_02183_1 crossref_primary_10_1111_os_12512 crossref_primary_10_1177_1054773820947984 crossref_primary_10_2147_CMAR_S250422 crossref_primary_10_1136_bmjopen_2018_021822 crossref_primary_10_1186_s12913_016_1536_x crossref_primary_10_3389_fpubh_2023_1300404 crossref_primary_10_1016_j_ijnss_2022_09_015 crossref_primary_10_3389_fonc_2022_983704 crossref_primary_10_1016_j_vhri_2017_05_004 crossref_primary_10_1111_irv_13180 crossref_primary_10_1186_s12889_021_10847_0 crossref_primary_10_1186_s12889_025_22203_7 crossref_primary_10_1080_13696998_2018_1470977 crossref_primary_10_1155_2021_9972386 crossref_primary_10_1007_s11136_020_02645_9 crossref_primary_10_1016_j_jval_2023_03_003 crossref_primary_10_1038_s41598_023_35002_0 crossref_primary_10_3389_fmed_2024_1451979 crossref_primary_10_1002_sim_8592 crossref_primary_10_1016_j_puhe_2015_10_009 crossref_primary_10_1186_s12879_023_08940_3 crossref_primary_10_1371_journal_pone_0184883 crossref_primary_10_1007_s40258_025_00954_z crossref_primary_10_1016_S2468_1253_21_00110_2 crossref_primary_10_1371_journal_pone_0234850 crossref_primary_10_1186_s12877_024_05646_2 crossref_primary_10_1097_MLR_0000000000001417 crossref_primary_10_1007_s00520_023_08231_2 crossref_primary_10_1038_s41598_017_15083_4 crossref_primary_10_3390_atmos12121551 crossref_primary_10_1111_dom_16325 crossref_primary_10_1111_1759_7714_13368 crossref_primary_10_1007_s11136_020_02524_3 crossref_primary_10_1007_s10067_023_06659_9 crossref_primary_10_1016_j_socscimed_2019_04_018 crossref_primary_10_3390_ijerph17041351 crossref_primary_10_1186_s13063_021_05392_5 crossref_primary_10_1177_0272989X15606903 crossref_primary_10_1007_s11136_019_02336_0 crossref_primary_10_1186_s12955_020_01324_0 crossref_primary_10_1097_CM9_0000000000002847 crossref_primary_10_1186_s12877_024_05249_x crossref_primary_10_1186_s12955_020_01325_z crossref_primary_10_1186_s12913_019_4206_y crossref_primary_10_2147_JAA_S460300 crossref_primary_10_1097_MAO_0000000000003907 crossref_primary_10_1371_journal_pone_0229652 crossref_primary_10_2215_CJN_06800619 crossref_primary_10_1111_ggi_14893 crossref_primary_10_1111_jan_16397 crossref_primary_10_1016_j_jamda_2019_02_024 crossref_primary_10_1371_journal_pone_0204118 crossref_primary_10_3390_ijerph16081314 crossref_primary_10_1016_j_envint_2019_105041 crossref_primary_10_1111_jgh_15238 crossref_primary_10_3402_gha_v9_32261 crossref_primary_10_1186_s12955_015_0347_9 crossref_primary_10_1007_s12325_023_02576_0 crossref_primary_10_1186_s12877_017_0679_x crossref_primary_10_1016_j_cjtee_2018_05_001 crossref_primary_10_1186_s12955_016_0499_2 crossref_primary_10_1016_j_jval_2020_11_012 crossref_primary_10_1136_jnnp_2016_314414 crossref_primary_10_1016_j_vhri_2020_07_580 crossref_primary_10_1007_s11136_018_2032_z crossref_primary_10_1080_15402002_2022_2025805 crossref_primary_10_1007_s40271_017_0220_5 crossref_primary_10_1186_s12955_024_02275_6 crossref_primary_10_2217_cer_2017_0069 crossref_primary_10_1186_s12874_020_01008_9 crossref_primary_10_1002_cam4_1817 crossref_primary_10_1016_j_jval_2018_05_008 crossref_primary_10_3390_ijerph17249261 crossref_primary_10_1016_j_lungcan_2021_12_009 crossref_primary_10_3390_ijerph14030224 crossref_primary_10_1007_s11136_023_03512_z crossref_primary_10_1002_pon_5160 crossref_primary_10_1007_s40273_022_01216_9 crossref_primary_10_1186_s12955_020_01409_w crossref_primary_10_1186_s12955_020_01632_5 crossref_primary_10_3389_fpubh_2020_580757 crossref_primary_10_1136_bmjopen_2023_081140 crossref_primary_10_1007_s11136_021_02883_5 crossref_primary_10_1007_s10389_023_02077_y crossref_primary_10_3389_fpubh_2022_955615 crossref_primary_10_1186_s12885_018_4855_y crossref_primary_10_1200_GO_24_00044 crossref_primary_10_3390_ijerph16081336 crossref_primary_10_3389_fphar_2022_916421 crossref_primary_10_1007_s40271_020_00466_z crossref_primary_10_1186_s12955_019_1175_0 crossref_primary_10_1007_s11136_020_02644_w crossref_primary_10_1007_s10198_024_01682_2 crossref_primary_10_1177_15347354211002919 crossref_primary_10_1016_j_jvacx_2023_100415 crossref_primary_10_1186_s12955_024_02309_z crossref_primary_10_1038_srep17301 crossref_primary_10_1186_s12886_023_03106_w crossref_primary_10_1136_bmjdrc_2024_004120 crossref_primary_10_1007_s11136_019_02292_9 crossref_primary_10_1007_s13555_023_01041_8 crossref_primary_10_1111_1753_0407_13473 crossref_primary_10_3389_ijph_2021_1604025 |
Cites_doi | 10.1016/S0167-6296(01)00130-8 10.1097/00005650-200202000-00006 10.1111/j.1524-4733.2009.00579.x 10.2165/00019053-199507060-00004 10.1002/hec.1124 10.1007/s11136-011-9903-x 10.1111/j.1524-4733.2008.00413.x 10.1097/01.mlr.0000252166.76255.68 10.1097/00005650-200503000-00003 10.1111/j.1524-4733.2008.00468.x 10.1016/S0929-6646(08)60078-9 10.1007/s11136-010-9678-5 10.1016/0168-8510(96)00822-6 10.47102/annals-acadmedsg.V32N5p685 10.1177/0272989X06286480 10.1097/00005650-199711000-00002 10.1002/hec.673 10.1186/1478-7954-1-11 10.1007/s11136-004-0612-6 10.1111/j.1524-4733.2008.00348.x 10.2165/11314120-000000000-00000 10.1016/j.jval.2010.11.016 |
ContentType | Journal Article |
Copyright | 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2015 INIST-CNRS Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – notice: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – notice: 2015 INIST-CNRS – notice: Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. |
DBID | 6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.jval.2014.05.007 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Public Health |
EISSN | 1524-4733 |
EndPage | 604 |
ExternalDocumentID | 25128053 28765635 10_1016_j_jval_2014_05_007 S1098301514018828 1_s2_0_S1098301514018828 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Asia China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6PF 7-5 7PT 8-1 8P~ 8UM AAEDT AAEDW AAFJI AAFWJ AAIKJ AAKOC AALRI AAMMB AAOAW AAPFB AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACPRK ACRLP ACRPL ACUHS ACVFH ACXQS ADBBV ADCNI ADEZE ADFHU ADMUD ADNMO ADVLN AEBSH AEFGJ AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AEYQN AFBPY AFEBI AFJKZ AFPUW AFRHN AFTJW AFXIZ AFZJQ AGCQF AGHFR AGQPQ AGTHC AGUBO AGXDD AGYEJ AIDQK AIDYY AIEXJ AIGII AIIAU AIIUN AIKHN AITUG AJAOE AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EFKBS EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB KOM LH4 M41 MO0 N9A O-L O9- OAUVE OIG OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SV3 T5K TEORI TUS W99 WIN WYUIH XG1 YFH Z5R ~G- 0SF 6I. AACTN AAFTH AAHHS ABVKL ACCFJ AEEZP AEQDE AFCTW AFKWA AIWBW AJBDE AJOXV AMFUW NCXOZ RIG SUPJJ AAIAV ABLVK ABYKQ AJBFU AKYCK EFLBG IXIXF LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c525t-56922538dbfa55e012798d6e741a670c62216d7015f97f19a249eb5e681ebe903 |
IEDL.DBID | IXB |
ISSN | 1098-3015 1524-4733 |
IngestDate | Fri Jul 11 16:53:00 EDT 2025 Mon Jul 21 05:24:33 EDT 2025 Wed Apr 02 07:24:01 EDT 2025 Thu Apr 24 23:02:53 EDT 2025 Tue Jul 01 03:45:22 EDT 2025 Fri Feb 23 02:33:42 EST 2024 Mon Feb 24 20:26:29 EST 2025 Tue Aug 26 18:38:38 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | EQ-5D utility social value set China TTO Asiatic Value Chinese Time trade-off Social aspect Public health |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/3.0 CC BY 4.0 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c525t-56922538dbfa55e012798d6e741a670c62216d7015f97f19a249eb5e681ebe903 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1098301514018828 |
PMID | 25128053 |
PQID | 1553712253 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1553712253 pubmed_primary_25128053 pascalfrancis_primary_28765635 crossref_citationtrail_10_1016_j_jval_2014_05_007 crossref_primary_10_1016_j_jval_2014_05_007 elsevier_sciencedirect_doi_10_1016_j_jval_2014_05_007 elsevier_clinicalkeyesjournals_1_s2_0_S1098301514018828 elsevier_clinicalkey_doi_10_1016_j_jval_2014_05_007 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-07-01 |
PublicationDateYYYYMMDD | 2014-07-01 |
PublicationDate_xml | – month: 07 year: 2014 text: 2014-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Value in health |
PublicationTitleAlternate | Value Health |
PublicationYear | 2014 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Shaw, Johnson, Coons (bib21) 2005; 43 Ma (bib13) 2010 Lamers, Stalmeier, Krabbe (bib28) 2006; 26 Dolan (bib20) 1997; 35 Feeny, Furlong, Torrance (bib3) 2002; 40 Brooks (bib4) 1996; 37 Lee, Nam, Chuang (bib15) 2009; 12 Lamers, McDonnell, Stalmeier (bib1) 2006; 15 Augustovski, Irazola, Velazquez (bib26) 2009; 12 Feeny, Furlong, Boyle, Torrance (bib2) 1995; 7 Bailey, Kind (bib7) 2010; 19 Luo, Chew, Fong (bib11) 2003; 32 Jelsma, Hansen, De Weerdt (bib25) 2003; 1 Knies, Evers, Candel (bib8) 2009; 27 Yang, Brazier, Tsuchiya, Coyne (bib23) 2009; 12 Herdman, Gudex, Lloyd (bib5) 2011; 20 Jo, Yun, Lee (bib19) 2008; 11 China guidelines for pharmacoeconomic evaluations (2011). 2011. Available from Chang, Tarn, Hsieh (bib12) 2007; 106 Szende, Oppe, Devlin (bib17) 2007 Dolan, Roberts (bib22) 2002; 40 [Accessed April 9, 2011]. Tsuchiya, Ikeda, Ikegami (bib14) 2002; 11 View on deepening the health care system reform by CPC Central Committee and the State Council. 2009. Available from Lamers (bib18) 2007; 45 [Accessed March 17, 2009]. Montejo, Correas-Lauffer, Maurino (bib27) 2011; 14 Brazier, Roberts, Deverill (bib6) 2002; 21 Kind (bib16) 2009 Wang, Kindig, Mullahy (bib10) 2005; 14 Feeny (10.1016/j.jval.2014.05.007_bib3) 2002; 40 Chang (10.1016/j.jval.2014.05.007_bib12) 2007; 106 10.1016/j.jval.2014.05.007_bib24 Feeny (10.1016/j.jval.2014.05.007_bib2) 1995; 7 Brooks (10.1016/j.jval.2014.05.007_bib4) 1996; 37 10.1016/j.jval.2014.05.007_bib9 Knies (10.1016/j.jval.2014.05.007_bib8) 2009; 27 Augustovski (10.1016/j.jval.2014.05.007_bib26) 2009; 12 Brazier (10.1016/j.jval.2014.05.007_bib6) 2002; 21 Luo (10.1016/j.jval.2014.05.007_bib11) 2003; 32 Kind (10.1016/j.jval.2014.05.007_bib16) 2009 Lamers (10.1016/j.jval.2014.05.007_bib1) 2006; 15 Lamers (10.1016/j.jval.2014.05.007_bib18) 2007; 45 Tsuchiya (10.1016/j.jval.2014.05.007_bib14) 2002; 11 Bailey (10.1016/j.jval.2014.05.007_bib7) 2010; 19 Lee (10.1016/j.jval.2014.05.007_bib15) 2009; 12 Szende (10.1016/j.jval.2014.05.007_bib17) 2007 Lamers (10.1016/j.jval.2014.05.007_bib28) 2006; 26 Wang (10.1016/j.jval.2014.05.007_bib10) 2005; 14 Montejo (10.1016/j.jval.2014.05.007_bib27) 2011; 14 Jelsma (10.1016/j.jval.2014.05.007_bib25) 2003; 1 Shaw (10.1016/j.jval.2014.05.007_bib21) 2005; 43 Ma (10.1016/j.jval.2014.05.007_bib13) 2010 Dolan (10.1016/j.jval.2014.05.007_bib22) 2002; 40 Dolan (10.1016/j.jval.2014.05.007_bib20) 1997; 35 Yang (10.1016/j.jval.2014.05.007_bib23) 2009; 12 Jo (10.1016/j.jval.2014.05.007_bib19) 2008; 11 Herdman (10.1016/j.jval.2014.05.007_bib5) 2011; 20 |
References_xml | – volume: 40 start-page: 113 year: 2002 end-page: 128 ident: bib3 article-title: Multiattribute and single-attribute utility functions for the health utilities index mark 3 system publication-title: Med Care – volume: 14 start-page: 119 year: 2005 end-page: 132 ident: bib10 article-title: Variation in Chinese population health related quality of life: results from a EuroQol study in Beijing, China publication-title: Qual Life Res – volume: 11 start-page: 341 year: 2002 end-page: 353 ident: bib14 article-title: Estimating an EQ-5D population value set: the case of Japan publication-title: Health Econ – volume: 12 start-page: 159 year: 2009 end-page: 166 ident: bib23 article-title: Estimating a preference-based single index from the Overactive Bladder Questionnaire publication-title: Value Health – volume: 14 start-page: 564 year: 2011 end-page: 570 ident: bib27 article-title: Estimation of a multiattribute utility function for the Spanish version of the TooL questionnaire publication-title: Value Health – volume: 21 start-page: 271 year: 2002 end-page: 292 ident: bib6 article-title: The estimation of a preference-based measure of health from the SF-36 publication-title: J Health Econ – volume: 40 start-page: 442 year: 2002 end-page: 446 ident: bib22 article-title: Modeling valuations for EQ-5D health states: an alternative model using differences in valuations publication-title: Value Health – year: 2010 ident: bib13 article-title: China Statistical Yearbook 2010 – reference: China guidelines for pharmacoeconomic evaluations (2011). 2011. Available from: – volume: 27 start-page: 767 year: 2009 end-page: 779 ident: bib8 article-title: Utilities of the EQ-5D: transferable or not? publication-title: Pharmacoeconomics – reference: . [Accessed April 9, 2011]. – volume: 45 start-page: 238 year: 2007 end-page: 244 ident: bib18 article-title: The transformation of utilities for health states worse than death: consequences for the estimation of EQ-5D value sets publication-title: Med Care – volume: 11 start-page: 1186 year: 2008 end-page: 1189 ident: bib19 article-title: Estimating quality weights for EQ-5D health states with the time trade-off method in South Korea publication-title: Value Health – volume: 1 start-page: 1 year: 2003 end-page: 10 ident: bib25 article-title: How do Zimbabweans value health states? publication-title: Popul Health Metr – volume: 37 start-page: 53 year: 1996 end-page: 72 ident: bib4 article-title: EuroQol: the current state of play publication-title: Health Policy – volume: 12 start-page: 587 year: 2009 end-page: 596 ident: bib26 article-title: Argentine valuation of the EQ-5D health states publication-title: Value Health – volume: 26 start-page: 173 year: 2006 end-page: 181 ident: bib28 article-title: Inconsistencies in TTO and VAS values for EQ-5D health states publication-title: Med Decis Making – volume: 35 start-page: 1095 year: 1997 end-page: 1108 ident: bib20 article-title: Modeling valuations for EuroQol health states publication-title: Med Care – volume: 15 start-page: 121 year: 2006 end-page: 132 ident: bib1 article-title: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies publication-title: Health Econ – year: 2007 ident: bib17 article-title: EQ-5D Value Sets: Inventory, Comparative Review and User Guide – volume: 32 start-page: 685 year: 2003 end-page: 690 ident: bib11 article-title: Validity and reliability of the EQ-5D self-report questionnaire in Chinese-speaking patients with rheumatic diseases in Singapore publication-title: Ann Acad Med Singapore – year: 2009 ident: bib16 article-title: A Revised Protocol for the Valuation of Health States Defined by the EQ-5D-3L Classification System: Learning the Lessons from the MVH Study publication-title: York: Centre for Health Economics, University of York – volume: 43 start-page: 203 year: 2005 end-page: 220 ident: bib21 article-title: US valuation of the EQ-5D health states: development and testing of the D1 valuation model publication-title: Med Care – volume: 7 start-page: 490 year: 1995 end-page: 502 ident: bib2 article-title: Multi-attribute health status classification systems: health utilities index publication-title: Pharmacoeconomics – volume: 12 start-page: 1187 year: 2009 end-page: 1193 ident: bib15 article-title: South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states publication-title: Value Health – reference: View on deepening the health care system reform by CPC Central Committee and the State Council. 2009. Available from: – volume: 20 start-page: 1727 year: 2011 end-page: 1736 ident: bib5 article-title: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) publication-title: Qual Life Res – volume: 19 start-page: 1145 year: 2010 end-page: 1154 ident: bib7 article-title: Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets publication-title: Qual Life Res – reference: . [Accessed March 17, 2009]. – volume: 106 start-page: 1023 year: 2007 end-page: 1031 ident: bib12 article-title: Taiwanese version of the EQ-5D: validation in a representative sample of the Taiwanese population publication-title: J Formos Med Assoc – year: 2009 ident: 10.1016/j.jval.2014.05.007_bib16 article-title: A Revised Protocol for the Valuation of Health States Defined by the EQ-5D-3L Classification System: Learning the Lessons from the MVH Study publication-title: York: Centre for Health Economics, University of York – ident: 10.1016/j.jval.2014.05.007_bib24 – volume: 21 start-page: 271 year: 2002 ident: 10.1016/j.jval.2014.05.007_bib6 article-title: The estimation of a preference-based measure of health from the SF-36 publication-title: J Health Econ doi: 10.1016/S0167-6296(01)00130-8 – volume: 40 start-page: 113 year: 2002 ident: 10.1016/j.jval.2014.05.007_bib3 article-title: Multiattribute and single-attribute utility functions for the health utilities index mark 3 system publication-title: Med Care doi: 10.1097/00005650-200202000-00006 – volume: 12 start-page: 1187 year: 2009 ident: 10.1016/j.jval.2014.05.007_bib15 article-title: South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states publication-title: Value Health doi: 10.1111/j.1524-4733.2009.00579.x – volume: 7 start-page: 490 year: 1995 ident: 10.1016/j.jval.2014.05.007_bib2 article-title: Multi-attribute health status classification systems: health utilities index publication-title: Pharmacoeconomics doi: 10.2165/00019053-199507060-00004 – year: 2007 ident: 10.1016/j.jval.2014.05.007_bib17 – volume: 15 start-page: 121 year: 2006 ident: 10.1016/j.jval.2014.05.007_bib1 article-title: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies publication-title: Health Econ doi: 10.1002/hec.1124 – volume: 20 start-page: 1727 year: 2011 ident: 10.1016/j.jval.2014.05.007_bib5 article-title: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) publication-title: Qual Life Res doi: 10.1007/s11136-011-9903-x – volume: 12 start-page: 159 year: 2009 ident: 10.1016/j.jval.2014.05.007_bib23 article-title: Estimating a preference-based single index from the Overactive Bladder Questionnaire publication-title: Value Health doi: 10.1111/j.1524-4733.2008.00413.x – volume: 45 start-page: 238 year: 2007 ident: 10.1016/j.jval.2014.05.007_bib18 article-title: The transformation of utilities for health states worse than death: consequences for the estimation of EQ-5D value sets publication-title: Med Care doi: 10.1097/01.mlr.0000252166.76255.68 – volume: 43 start-page: 203 year: 2005 ident: 10.1016/j.jval.2014.05.007_bib21 article-title: US valuation of the EQ-5D health states: development and testing of the D1 valuation model publication-title: Med Care doi: 10.1097/00005650-200503000-00003 – volume: 12 start-page: 587 year: 2009 ident: 10.1016/j.jval.2014.05.007_bib26 article-title: Argentine valuation of the EQ-5D health states publication-title: Value Health doi: 10.1111/j.1524-4733.2008.00468.x – volume: 106 start-page: 1023 year: 2007 ident: 10.1016/j.jval.2014.05.007_bib12 article-title: Taiwanese version of the EQ-5D: validation in a representative sample of the Taiwanese population publication-title: J Formos Med Assoc doi: 10.1016/S0929-6646(08)60078-9 – year: 2010 ident: 10.1016/j.jval.2014.05.007_bib13 – volume: 40 start-page: 442 year: 2002 ident: 10.1016/j.jval.2014.05.007_bib22 article-title: Modeling valuations for EQ-5D health states: an alternative model using differences in valuations publication-title: Value Health – volume: 19 start-page: 1145 year: 2010 ident: 10.1016/j.jval.2014.05.007_bib7 article-title: Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets publication-title: Qual Life Res doi: 10.1007/s11136-010-9678-5 – volume: 37 start-page: 53 year: 1996 ident: 10.1016/j.jval.2014.05.007_bib4 article-title: EuroQol: the current state of play publication-title: Health Policy doi: 10.1016/0168-8510(96)00822-6 – volume: 32 start-page: 685 year: 2003 ident: 10.1016/j.jval.2014.05.007_bib11 article-title: Validity and reliability of the EQ-5D self-report questionnaire in Chinese-speaking patients with rheumatic diseases in Singapore publication-title: Ann Acad Med Singapore doi: 10.47102/annals-acadmedsg.V32N5p685 – volume: 26 start-page: 173 year: 2006 ident: 10.1016/j.jval.2014.05.007_bib28 article-title: Inconsistencies in TTO and VAS values for EQ-5D health states publication-title: Med Decis Making doi: 10.1177/0272989X06286480 – volume: 35 start-page: 1095 year: 1997 ident: 10.1016/j.jval.2014.05.007_bib20 article-title: Modeling valuations for EuroQol health states publication-title: Med Care doi: 10.1097/00005650-199711000-00002 – ident: 10.1016/j.jval.2014.05.007_bib9 – volume: 11 start-page: 341 year: 2002 ident: 10.1016/j.jval.2014.05.007_bib14 article-title: Estimating an EQ-5D population value set: the case of Japan publication-title: Health Econ doi: 10.1002/hec.673 – volume: 1 start-page: 1 year: 2003 ident: 10.1016/j.jval.2014.05.007_bib25 article-title: How do Zimbabweans value health states? publication-title: Popul Health Metr doi: 10.1186/1478-7954-1-11 – volume: 14 start-page: 119 year: 2005 ident: 10.1016/j.jval.2014.05.007_bib10 article-title: Variation in Chinese population health related quality of life: results from a EuroQol study in Beijing, China publication-title: Qual Life Res doi: 10.1007/s11136-004-0612-6 – volume: 11 start-page: 1186 year: 2008 ident: 10.1016/j.jval.2014.05.007_bib19 article-title: Estimating quality weights for EQ-5D health states with the time trade-off method in South Korea publication-title: Value Health doi: 10.1111/j.1524-4733.2008.00348.x – volume: 27 start-page: 767 year: 2009 ident: 10.1016/j.jval.2014.05.007_bib8 article-title: Utilities of the EQ-5D: transferable or not? publication-title: Pharmacoeconomics doi: 10.2165/11314120-000000000-00000 – volume: 14 start-page: 564 year: 2011 ident: 10.1016/j.jval.2014.05.007_bib27 article-title: Estimation of a multiattribute utility function for the Spanish version of the TooL questionnaire publication-title: Value Health doi: 10.1016/j.jval.2010.11.016 |
SSID | ssj0006325 |
Score | 2.5392265 |
Snippet | To generate a Chinese general population–based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method.
The study sample... AbstractObjectiveTo generate a Chinese general population–based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method.... To generate a Chinese general population-based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method. The study sample... To generate a Chinese general population-based three-level EuroQol five-dimensios (EQ-5D-3L) social value set using the time trade-off method.OBJECTIVETo... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 597 |
SubjectTerms | Adolescent Adult Biological and medical sciences China Data Collection EQ-5D Female General aspects Health Status Humans Internal Medicine Least-Squares Analysis Linear Models Male Medical sciences Middle Aged Miscellaneous Models, Econometric Models, Statistical Planification. Prevention (methods). Intervention. Evaluation Public Health Public health. Hygiene Public health. Hygiene-occupational medicine Quality of Life Quality-Adjusted Life Years social value set Surveys and Questionnaires Time Factors TTO utility Young Adult |
Title | Chinese Time Trade-Off Values for EQ-5D Health States |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1098301514018828 https://www.clinicalkey.es/playcontent/1-s2.0-S1098301514018828 https://dx.doi.org/10.1016/j.jval.2014.05.007 https://www.ncbi.nlm.nih.gov/pubmed/25128053 https://www.proquest.com/docview/1553712253 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9RAFH_UCiJI0ao1apcRpBc7biaTSTLHtrasSmvFVvY2ZDMz0FK2i9keeunf7nuZyS7FWsFjwjwyeZ-_Yd4HwHuPUVlnjeROi4rneZnx2sqU68w6La2tfddI-_CoGJ3mX8ZqvAJ7fS0MpVVG3x98euet45th5OZwdnY2_CFSXaF6KjoiIE6kgl-ZV10R33h34Y0L2Q1epcWcVsfCmZDjdY7SpPSuvOveSSNl7w5OT2Z1iyzzYdbF38FoF5QOnsJaRJNsJ2z4Gay46To8Ooz35euwdRw6U19vs5NloVW7zbbY8bJn9fVzUDRH27WOUUkIwwBmHf_mPftZX-AGGCJbtv-dq08slC2xgFFfwOnB_sneiMeJCrxRmZpzVWi0X1nZia-VcnTtrCtbOIQVdVGmTZFlorAlssnr0gtd4-HMTZQrKoHC1ql8CavTy6l7BUyqSS7xdIgx3ua5R7tHggaFK0pJTesTED0rTRPbjdPUiwvT55WdG2K_IfabVBlkfwIfFjSz0Gzj3tWyl5Dpy0jR8RmMBfdSlXdRuTbabmuEaTOTmj_0KwG1oLylov_84uCW-ix-DQ-riKalSuBdr08GjZtubOqpu7zCrSglS0EiS2AjKNqSGqFahS709X9u6w08pqeQevwWVue_rtwmAqz5ZAAPPt6IATzc-fx1dDTo7Ok3IWsfzA |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4aQxpICMFgEGDDk9BemNU4jp34EXZRd-kYokN9s9LYljZNXUW6h_17jmOn1cTYpL0mPopzrp_lcwH44jAqq6zm1CpW0jwvMloZnlKVGau4MZVrG2kPTmT_LD8cidES7HS1MD6tMvr-4NNbbx2f9CI3e9Pz894vlqoS1VP4IwLixPIJPEU0IL1qH4y-z92x5O3kVb-a-uWxciYkeV2gOH1-V9627_QzZe-OTi-mVYM8c2HYxf_RaBuV9l_Bywgnybew49ewZCersDKIF-arsHUaWlPfbJPhotKq2SZb5HTRtPrmDQg_SNs2lviaEIIRzFj6wznyu7rEDRCEtmTvJxW7JNQtkQBS38LZ_t5wp0_jSAVai0zMqJAKDZiXZuwqIay_d1alkRZxRSWLtJZZxqQpkE1OFY6pCk9ndiysLBlKW6V8DZYnVxP7HggX45zj8RCDvMlzh4aPBDVKlxXcd61PgHWs1HXsN-7HXlzqLrHsQnv2a89-nQqN7E_g65xmGrpt3LuadxLSXR0pej6NweBequIuKttE4200002mU_2PgiUg5pS3dPTBL27cUp_5r-FpFeE0Fwlsdvqk0br9lU01sVfXuBUheMG8yBJ4FxRtQY1YrUQf-uGR2_oMz_rDwbE-Pjg5-gjP_ZuQh_wJlmd_ru06oq3ZeKO1pr_l8SBn |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chinese+Time+Trade-Off+Values+for+EQ-5D+Health+States&rft.jtitle=Value+in+health&rft.au=Liu%2C+Gordon+G.&rft.au=Wu%2C+Hongyan&rft.au=Li%2C+Minghui&rft.au=Gao%2C+Chen&rft.date=2014-07-01&rft.issn=1098-3015&rft.volume=17&rft.issue=5&rft.spage=597&rft.epage=604&rft_id=info:doi/10.1016%2Fj.jval.2014.05.007&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jval_2014_05_007 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10983015%2FS1098301514X00057%2Fcov150h.gif |